Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 31 entries
View as:

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase: N/A Priority: Normal
NCT ID: NCT06829459 Org: User:
Start: 04/03/25 End: 02/15/29 Due: 02/15/30

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06735391 Org: User:
Start: 10/23/24 End: 05/30/29 Due: 05/30/30

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04448379 Org: User:
Start: 06/29/20 End: 06/30/22 Due: 06/30/23

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Phase: N/A Priority: Normal
NCT ID: NCT04255576 Org: User:
Start: 10/10/19 End: 10/31/23 Due: 10/31/24

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05513664 Org: User:
Start: 09/30/22 End: 08/31/23 Due: 08/31/24

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT05278338 Org: User:
Start: 04/21/22 End: 03/31/24 Due: 03/31/25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06892431 Org: User:
Start: 04/01/25 End: 04/30/27 Due: 04/30/28

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05132777 Org: User:
Start: 11/20/21 End: 09/30/24 Due: 09/30/25

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05427383 Org: User:
Start: 04/07/22 End: 11/30/26 Due: 11/30/27

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06908772 Org: User:
Start: 04/01/25 End: 01/31/30 Due: 01/31/31

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05838066 Org: User:
Start: 07/23/23 End: 12/31/27 Due: 12/31/28

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06391944 Org: User:
Start: 11/21/21 End: 11/21/26 Due: 11/21/27

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT07029139 Org: User:
Start: 06/30/25 End: 03/01/29 Due: 03/01/30

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04630522 Org: User:
Start: 10/31/20 End: 03/31/23 Due: 03/31/24

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Phase: N/A Priority: Normal
NCT ID: NCT06221072 Org: User:
Start: 04/05/24 End: 05/31/28 Due: 05/31/29

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06380348 Org: User:
Start: 04/26/24 End: 03/26/28 Due: 03/26/29

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03550508 Org: User:
Start: 05/21/18 End: 12/01/19 Due: 12/01/20

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06846437 Org: User:
Start: 02/18/25 End: 12/31/28 Due: 12/31/29

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06877650 Org: User:
Start: 04/11/25 End: 03/30/29 Due: 03/30/30

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04689100 Org: User:
Start: 04/11/17 End: 06/30/22 Due: 06/30/23

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06998771 Org: User:
Start: 06/15/25 End: 12/31/29 Due: 12/31/30

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Phase: N/A Priority: Normal
NCT ID: NCT05397938 Org: User:
Start: 06/15/22 End: 06/01/23 Due: 06/01/24

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06747338 Org: User:
Start: 12/16/24 End: 12/16/27 Due: 12/16/28

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

Phase: N/A Priority: Normal
NCT ID: NCT06564467 Org: User:
Start: 07/23/24 End: 07/10/25 Due: 07/10/26

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Phase: N/A Priority: Normal
NCT ID: NCT05402865 Org: User:
Start: 11/10/21 End: 02/18/22 Due: 02/18/23